



ASX ANNOUNCEMENT

25 November 2009

Second VitroGro® Patent Allowed in USA

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** announced today that the United States Patent and Trademark Office has issued a Notice of Allowance to the Company for the second core VitroGro® patent "Growth Factor Complexes and Modulation of Cell Migration and Growth".

This means that this patent has been accepted by the United States Patent and Trademark Office and will be granted when the issue fee is paid. This payment has been made.

The acceptance of this patent in the family of VitroGro® Intellectual Property (IP) in the USA follows the prior granting of VitroGro® patents in the USA, South Korea, South Africa, Australia and New Zealand.

The CEO of Tissue Therapies Ltd, Dr Steven Mercer said, "The acceptance of the second core VitroGro® patent in the USA substantially strengthens the IP position and commercial value of the company."

"The patent examination process is progressing well in other jurisdictions and I anticipate that we will be able to announce the granting of further patents over the next 12 months."

Further information: Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938
Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic skin ulcers and burns.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com